South Plainfield, NJ– November 3, 2015 – PuraCap Pharmaceutical LLC announced today the introduction of a new product, EpiCeram-L™ Lip Care, a unique lip care formulation with an exclusive delivery system for the treatment of dry lip conditions.  PuraCap Pharmaceutical is the maker of EpiCeram^® Controlled Release Skin Barrier Emulsion, a leading prescription product indicated for the treatment of dry skin conditions and management of burning and itching associated with various skin conditions including atopic dermatitis.  The introduction of EpiCeram-L adds to PuraCap’s growing portfolio of dermatology products.

EpiCeram-L Lip Care is a unique lip care formulation with an exclusive delivery system developed specifically for severely chapped, dry, or cracked lips. EpiCeram-L Lip Care uses patented MultiSal™ technology to deliver 3 essential lipids – ceramides, free fatty acids and cholesterol in an all natural, steroid-free, paraben-free, fragrance-free, and color-free formulation.  EpiCeram-L Lip Care is available exclusively through prescribing healthcare professionals.

“PuraCap has a strong, growing portfolio of dermatology products and EpiCeram-L Lip Care is an exciting new addition,” said Dahai Guo, CEO of PuraCap Pharmaceutical LLC.  “We have listened to the needs of our customers and are pleased to introduce EpiCeram-L Lip Care.”

“Now there is a new option for patients who suffer from severely chapped, dry or cracked lips,” says Elise Klein, Vice President and General Manager of PuraCap’s Branded Rx division.  “We look forward to continuing to meet the needs of our physicians and patients.” Physicians will be able to dispense EpiCeram-L directly to their patients from the office, which will make it very easy for patients to get the lip balm and begin treatment immediately. EpiCeram-L will be distributed through a patented web based ordering system. The program is designed to provide physicians easy access to PuraCap’s growing portfolio of dermatology products.

About PuraCap Pharmaceutical LLC

PuraCap Pharmaceutical LLC is an emerging, fully integrated pharmaceutical company with expertise in product development, manufacturing, and bringing affordable, world-class quality products to their customers.  The PuraCap corporate structure supports a two-pronged approach for global growth with dedicated companies in the areas of prescription brands (PuraCap Pharmaceutical) as well as prescription generics and OTC and private label brands.   PuraCap Pharmaceutical continues to innovate using our soft gel expertise and developing other soft gel options. Go to www.puracap.com for more information.

Forward-Looking Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which PuraCap Pharmaceutical LLC does business, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.
Media Contact:
Elise Klein
Vice President and General Manager
Branded Rx Products
Elise.klein@puracappharma.com
908-941-5456 ext. 640

South Plainfield, NJ–November 11, 2015 – PuraCap Pharmaceutical LLC. is pleased to announce that the US Food and Drug Administration (FDA) has completed a successful inspection of its affiliated soft gelatin capsule manufacturing facility, Humanwell PuraCap Pharmaceutical (Wuhan) Co, Ltd , located in Wuhan, Hubei Province China. The inspection confirmed that the site is compliant with Current Good Manufacturing Practices, and NO Form 483 observations were issued. This FDA inspection took place on May 18 through May 22, 2015.
Dahai Guo, Chief Executive Officer commented, “ This successful inspection is the culmination of years of planning, development and training to achieve our goal of building a world class pharmaceutical manufacturing facility in China. It reflects the tireless work of the Humanwell PuraCap team of manufacturing and quality professionals.”
Xiaofeng Meng, VP of Global Regulatory and Quality added, “We have always measured our cGMP and Quality performance and have consistently achieved the highest potential scores on outside audits from global customers as well as 3rd-party authority, such as UL-STR, Intertek etc. An FDA inspection without observations is a testimony to our commitment to world-class quality and continuous improvement.”
About PuraCap Pharmaceutical LLC
PuraCap Pharmaceutical LLC is an emerging, fully integrated pharmaceutical company with expertise in product development, manufacturing, and bringing affordable, world-class quality products to their customers. The PuraCap corporate structure supports a two-pronged approach for global growth with dedicated companies in the areas of prescription brands (PuraCap Pharmaceutical) as well as prescription generics and OTC drugs. PuraCap Pharmaceutical continues to innovate using our soft gel expertise and developing other oral solid options. Go to www.puracap.com for more information.
Forward-Looking Statement
All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which PuraCap Pharmaceutical LLC does business, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.
Media Contact:
Elise Klein
Vice President and General Manager
Branded Rx Products
Elise.klein@puracappharma.com
908-941-5456 ext. 640

PuraCap™ Pharmaceutical Introduces Unique EpiCeram® 225g Airless Pump

EpiCeram® Controlled Release Skin Barrier Emulsion Now Offers Dosing Flexibility with 2 Sizes

South Plainfield, NJ – July 7, 2014  PuraCap™ Pharmaceutical today announced the newest addition to the EpiCeram® product line, the EpiCeram® 225g Airless Pump.  The unique airless pump gives patients more EpiCeram® to treat any size area of atopic dermatitis.  The special dispensing system allows for more control, delivering EpiCeram® consistently and precisely in a convenient to use, portable, pump action dispenser.  The EpiCeram® Airless Pump also offers cost savings with BID dosing and a controlled release formulation that is long lasting.

Read more »

Max Baucus, US Ambassador to China visits Wuhan Softgel Capsule Manufacturing Plant in Wuhan China

SOUTH PLAINFIELD, N.J., May 19, 2014 /PRNewswire/ — PuraCap Pharmaceutical today announced the visit of Max Baucus, US Ambassador to China, to the PuraCap Softgel Capsule Manufacturing Plant in Wuhan, China on May 14, 2014. Ambassador Baucus had the opportunity to tour the entire manufacturing plant. This visit is part of the Ambassador’s plan to visits enterprises throughout China. Ambassador Baucus is the 11th Ambassador to China, assuming office on Mar 20, 2014. He was accompanied by Vlad Lipshutz, US Consulate General in Wuhan.

“The Wuhan facility is a state of the art softgel capsule manufacturing plant and we are pleased that Ambassador Baucus had an opportunity to visit and observe manufacturing operations. We are excited that Ambassador Baucus chose to visit the PuraCap-China manufacturing facility so early in his tenure as Ambassador,” said Dahai Guo, CEO of PuraCap. Plant Director Maboob Rahman had the opportunity to demonstrate first-hand, the quality standards developed and implemented to meet strict US FDA cGMP manufacturing requirements. PuraCap is currently manufacturing and importing capsules to supply the US OTC market. Many US customers are now being supplied with softgel capsule pharmaceutical products manufactured by PuraCap.

About the Humanwell PuraCap Pharmaceutical (Wuhan), Ltd Softgel capsule Manufacturing Facility

Operational since 2011, the Wuhan pharmaceutical manufacturing facility was designed and built to meet and exceed regulatory standards, both from the US FDA, EMEA and CFDA quality requirements. The 140,000 sq foot facility is located in the capital of Hubei in Wuhan, China.

About PuraCap™ Pharmaceutical LLC
PuraCap™ Pharmaceutical LLC is a fully integrated pharmaceutical company with expertise in product development, manufacturing and bringing affordable, world-class quality products to their customers. The PuraCap™ corporate structure supports their three-prong approach for global growth with dedicated companies in the areas of prescription brands, PuraCap™ Pharmaceutical LLC; prescription generics, PuraCap™ Laboratories Inc.; and OTC and Private Label products, PuraVation™ Pharmaceuticals Inc. For more information on PuraCap™ Pharmaceutical LLC, visit the company’s website at http://www.PuraCap.com .

Contact: Elise Klein
908.941.5456; Email

SOURCE PuraCap Pharmaceutical LLC

Copyright (C) 2014 PR Newswire. All rights reserved

StayinFront to Provide PuraCap With Sales Force Automation Software and Services for Field Sales Force

FAIRFIELD, NJ–(Marketwired – Jun 17, 2013) – PuraCap Pharmaceuticals, an emerging, global pharmaceutical company headquartered in South Plainfield, New Jersey, has selected StayinFront Inc., as its customer relationship management partner. PuraCap will deploy StayinFront’s mobile CRM, StayinFront TouchRx® to its national sales reps along with StayinFront EdgeRx® for its management team in July 2013.

PuraCap is transitioning its sales force from a contract sales organization to an in-house sales team and sought out an established partner with extensive experience in the field of pharmaceutical CRM. StayinFront provided a PDMA-compliant solution designed to meet the specific regulatory and process requirements for its pharmaceutical inventory and sampling programs.

“StayinFront provided everything we needed in a CRM solution to optimize our sales efforts and give our management critical insight,” said Richard Hooten, VP Sales & Managed Markets. “The functionality of the technology, their in-depth experience in the pharmaceutical space and ability for rapid deployment were all key factors in our decision.”

Ken Arbadji, Vice President Sales, North America at StayinFront, said, “We are pleased to be partnering with PuraCap in their efforts to internalize operations and maximize their product sales. We are the leader in providing a total biopharma sales solution on iPads — particularly selling tools like Closed Loop Marketing (CLM) and mobile analytics. Advanced, industry-focused technology, in combination with our agility and full service approach, makes us an ideal choice for small to mid-sized pharmaceutical companies.”

About PuraCap Pharmaceutical
PuraCap Pharmaceutical LLC is an emerging, fully-integrated pharmaceutical company with expertise in product development, manufacturing and bringing affordable, world-class quality products to their customers. The PuraCap corporate structure supports their three-prong approach for global growth with dedicated companies in the areas of prescription brands, PuraCap Pharmaceutical LLC; prescription generics, PuraCap Laboratories Inc.; and OTC and Private Label products, PuraVation™ Pharmaceuticals Inc. For more information on PuraCap Pharmaceutical LLC, visit the company’s website at www.PuraCap.com.

About StayinFront
StayinFront is an innovative global provider of enterprise-wide customer relationship management software, mobile sales force effectiveness and on-demand CRM solutions. StayinFront has been chosen as a strategic partner by many of the world’s top life sciences, consumer goods and business-to-business companies, improving efficiencies in over 65 countries and more than 25 languages. Headquartered in Fairfield, NJ, USA, StayinFront has offices in the United Kingdom, Ireland, India, Australia, Singapore and New Zealand. For more details about StayinFront CRM solutions or to experience an online demonstration, visit www.stayinfront.com.

South Plainfield, NJ, May 22,2013–Team EpiCeram is proud to announce its support of the National Eczema Association’s “Itching for a Cure” walk in New Jersey on June 8, 2013.  Working together with the National Eczema Association, Team EpiCeram hopes to build awareness of eczema and help raise funds for a cure.

More than 30 million Americans suffer from eczema (or atopic dermatitis), an incurable disease of the skin, which is characterized by chronic itch and inflammation.

Click here to download full Press Release
Read more »

September 22, 2012 on Fox Business Network

Boca Raton, FL (TBD) — Multi-media Productions (USA) is pleased to announce that PuraCap Pharmaceutical has been selected to appear on 21st Century Business, an award winning international television series.

PuraCap Pharmaceutical (www.puracap.com) is an emerging, global pharmaceutical company headquartered in South Plainfield, New Jersey, USA. PuraCap Pharmaceutical is a fully integrated pharmaceutical company with expertise in product development, manufacturing and bringing affordable, world-class quality products to their customers.

Read more »